Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Beats Estimates By $0.31 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31, FiscalAI reports. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $69.20 million. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Third-quarter revenue rose 24% year over year to $69.8 million, driven by continued FANAPT growth, favorable HETLIOZ shipment timing, and early NEREUS sales. FANAPT prescriptions increased 25% year over year, while NEREUS prescriptions and unique prescribers each more than doubled sequentially.
• Vanda expects to launch BYSANTI in the fourth quarter of 2026, with commercial supplies nearly ready, and is preparing for a potential Quimilza launch in the first half of 2027 if the FDA approves its GPP application by the December 12 PDUFA date.
• Positive Phase III results could expand NEREUS into prevention of GLP-1-associated vomiting and HETLIOZ into delayed sleep-wake phase disorder. Management plans to discuss both programs with the FDA and pursue supplemental applications.
• Operating expenses declined 18% sequentially to $93.3 million as major development and launch-preparation activities concluded, and management expects further reductions in coming quarters.
• Vanda ended September with $140.5 million in cash, down $123.4 million from year-end 2025, and expects 2026 cash burn to exceed 2025 levels. HETLIOZ revenue remains vulnerable to generic competition and specialty-pharmacy inventory normalization, while NEREUS 2026 revenue is expected to remain below $10 million.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA traded up $0.01 during mid-day trading on Wednesday, reaching $4.00. The company had a trading volume of 1,996,913 shares, compared to its average volume of 1,491,518. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The stock has a market cap of $241.85 million, a PE ratio of -0.86 and a beta of 0.69. The company has a 50-day moving average price of $4.88 and a two-hundred day moving average price of $6.27. Vanda Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $9.94.

Key Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: NEREUS delivered positive Phase III results. The therapy significantly reduced GLP-1-induced vomiting, including a 27% reduction in patients experiencing any vomiting, a 60% reduction in frequent multi-day vomiting and an 81% reduction in extreme vomiting. The data could support NEREUS’s commercial opportunity as GLP-1 drug use expands. Vanda NEREUS Phase III results
• Positive Sentiment: Revenue and operating trends improved according to Vanda’s official release. Q3 total revenue rose 24% year over year to $69.8 million, driven by Fanapt and the early NEREUS launch, while operating expenses declined 18% from the second quarter to $93.3 million. BYSANTI is expected to launch in the fourth quarter, adding another potential revenue source. Vanda third-quarter 2026 financial results
• Neutral Sentiment: Quimilza remains an important regulatory catalyst. Vanda’s biologics license application for generalized pustular psoriasis is under FDA review, with a target action date of December 12, 2026. Approval could materially expand the company’s commercial prospects, but the outcome remains uncertain.
• Negative Sentiment: Vanda remains unprofitable and is consuming cash. The company reported a quarterly loss of $0.37 per share, although this was better than the consensus estimate of a $0.68 loss. Third-party reporting cited a $22.6 million net loss, $31.1 million in operating cash use and $61.9 million in cash, highlighting ongoing funding and execution risks. Vanda earnings report

Analyst Ratings Changes

VNDA has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Monday, October 5th. B. Riley Financial restated a “buy” rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Oppenheimer started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Zacks Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.08.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.